Bionano Genomics IncQ) expected to post a loss of $6.00 a share - Earnings Preview
Bionano Genomics IncQ) is anticipated to report a loss of $6.00 per share and a 42.2% decline in quarterly revenue, dropping to $6.2 million from $10.72 million year-over-year. The company's guidance for revenue was between $7.90 million and $8.10 million. Analysts maintain a "hold" rating with no strong buy recommendations, and the median 12-month price target is $60.00, significantly higher than its last closing price of $3.07.
Bionano Genomics Inc (BNGO.OQ) (BNGO.O) is expected to show a fall in quarterly revenue when it reports results on March 31 for the period ending December 31 2024
The San Diego California-based company is expected to report a 42.2% decrease in revenue to $6.2 million from $10.72 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company’s guidance on January 13 2025, for the period ended December 31, was for revenue between $7.90 million and $8.10 million.
LSEG’s mean analyst estimate for Bionano Genomics Inc is for a loss of $6.00 per share.
The current average analyst rating on the shares is “hold” and the breakdown of recommendations is no “strong buy” or “buy,” 2 “hold” and no “sell” or “strong sell.”
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street’s median 12-month price target for Bionano Genomics Inc is $60.00, above its last closing price of $3.07. This summary was machine generated March 28 at 20:52 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
